## Deep Inferior Epigastric Perforator Flap (DIEP) Post-Op [1706]

General	
Common Present on Admission Diagnosis	
[] Acidosis	Post-op
[] Acute Post-Hemorrhagic Anemia	Post-op
Acute Renal Failure	Post-op
[] Acute Respiratory Failure	Post-op
[] Acute Thromboembolism of Deep Veins of Lower Extremities	Post-op
[] Anemia	Post-op
[] Bacteremia	Post-op
Bipolar disorder, unspecified	Post-op
Cardiac Arrest	Post-op
[] Cardiac Dysrhythmia	Post-op
Cardiogenic Shock	Post-op
Decubitus Ulcer	Post-op
Dementia in Conditions Classified Elsewhere	Post-op
Disorder of Liver	Post-op
[] Electrolyte and Fluid Disorder	Post-op
[] Intestinal Infection due to Clostridium Difficile	Post-op
Methicillin Resistant Staphylococcus Aureus Infection	Post-op
Obstructive Chronic Bronchitis with Exacerbation	Post-op
Other Alteration of Consciousness	Post-op
Other and Unspecified Coagulation Defects	Post-op
Other Pulmonary Embolism and Infarction	Post-op
Phlebitis and Thrombophlebitis	Post-op
Protein-calorie Malnutrition	Post-op
Psychosis, unspecified psychosis type	Post-op
Schizophrenia Disorder	Post-op
Sepsis	Post-op
[] Septic Shock	Post-op
Septicemia	Post-op
Type II or Unspecified Type Diabetes Mellitus with	Post-op
Mention of Complication, Not Stated as Uncontrolled	1 03t-op
[] Urinary Tract Infection, Site Not Specified	Post-op
Elective Outpatient, Observation, or Admission (Single	
( ) Elective outpatient procedure: Discharge following routine recovery	Routine, Continuous, PACU & Post-op
() Outpatient observation services under general	Admitting Physician:
supervision	Patient Condition:
	Bed request comments:
	PACU & Post-op
() Outpatient in a bed - extended recovery	Admitting Physician:
	Bed request comments:
	PACU & Post-op
() Admit to Inpatient	Admitting Physician:
	Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital services for two or more midnights.
	PACU & Post-op
	1 7.00 a 1 00t op

Admission	or Observat	ion (Single	Respo	nse)
Patient ha	as active outp	atient statu	s order	on file

() Admit to Inpatient	Admitting Physician: Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	PACU & Post-op
() Outpatient observation services under general	Admitting Physician:
supervision	Patient Condition:
	Bed request comments:
() <b>Q</b> ( ) ( ) ( ) ( ) ( )	PACU & Post-op
() Outpatient in a bed - extended recovery	Admitting Physician:
	Bed request comments:
() <b>T</b> ( ( ( )	PACU & Post-op
() Transfer patient	Level of Care:
	Bed request comments:
( ) Poture to provious bad	Scheduling/ADT
() Return to previous bed	Routine, Until discontinued, Starting S, Scheduling/ADT
Admission (Single Response) Patient has active status order on file	
() Admit to inpatient	Admitting Physician: Level of Care:
	Patient Condition:
	Bed request comments:
	Certification: I certify that based on my best clinical judgment
	and the patient's condition as documented in the HP and
	progress notes, I expect that the patient will need hospital
	services for two or more midnights.
	PACU & Post-op
() Transfer patient	Level of Care:
	Bed request comments:
	Scheduling/ADT
() Return to previous bed	Routine, Until discontinued, Starting S, Scheduling/ADT
Transfer (Single Response)	
Patient has active inpatient status order on file	
() Transfer patient	Level of Care:
· ·	Bed request comments:
	Scheduling/ADT
() Return to previous bed	Routine, Until discontinued, Starting S, Scheduling/ADT
Code Status	
[] Full Code	Code Status decision reached by:
••	Post-op
DNR (Do Not Resuscitate) (Selection Required)	·
DNR (Do Not Resuscitate)	Did the patient/surrogate require the use of an interpreter?
,	Did the patient/surrogate require the use of an interpreter?
	Does patient have decision-making capacity?
	Post-op

[] Consult to Palliative Care Service	Priority: Reason for Consult? Order?
	Name of referring provider: Enter call back number:
[] Consult to Social Work	Reason for Consult: Post-op
[] Modified Code	Did the patient/surrogate require the use of an interpreter? Did the patient/surrogate require the use of an interpreter? Does patient have decision-making capacity? Modified Code restrictions: Post-op
[] Treatment Restrictions	I understand that if the patient is NOT in a cardiopulmonary arrest, the selected treatments will NOT be provided. I understand that all other unselected medically indicated treatments will be provided.  Treatment Restriction decision reached by: Specify Treatment Restrictions: Post-op
Isolation	
[] Airborne isolation status	
[] Airborne isolation status	Details
[] Mycobacterium tuberculosis by PCR - If you suspect Tuberculosis, please order this test for rapid diagnostics.	Once, Sputum, Post-op
[] Contact isolation status	Details
Droplet isolation status	Details
[] Enteric isolation status	Details
Precautions	
[] Aspiration precautions	Post-op
[] Fall precautions	Increased observation level needed: Post-op
[] Latex precautions	Post-op
[] Seizure precautions	Increased observation level needed: Post-op
Nursing	
Vital Signs	
[X] Vital signs - T/P/R/BP	Routine, Every 15 min Perform vital signs every 15 minutes x 2 hours, every 30 minutes x 2 hours, and every hour after that., Post-op
[] Vital signs - T/P/R/BP every hour	Routine, Every hour, Post-op
Activity/Position	
[] Strict bed rest	Routine, Until discontinued, Starting S Head of Bed elevated 45 degrees, bed in flex position at hips., Post-op
[] Head of bed 45 degrees	Routine, Until discontinued, Starting S Head of bed: 45 degrees 45 degrees in breast reconstruction patients, Post-op
[] Patient position: Semi-Fowler's	Routine, Until discontinued, Starting S Position: semi-Fowler's Additional instructions: With bed flexed in semi-fowler's (lawn chair) position, Post-op

[] Up in chair on postop Day # ***	Routine, Until discontinued, Starting S Specify: Up in chair Additional modifier: to chair on PostOp Day # ***
[] Up in chair post operative Day #1	Post-op  Routine, Until discontinued, Starting S Specify: Up in chair Additional modifier: Post Operative Day #1. Sitting trial in recliner (NOT Cardiac Chair) after seen by the plastics service. Please refer to the Sitting Trial Protocol. If the sitting trial goes well, ie no changes in the doppler signals or flap perfusion, the patient will be ready for transfer to Acute Care Unit Post-op
[] Ambulate with assistance	Routine, 3 times daily Specify: with assistance,in hall On PostOp Day # *** ambulate in hallway WITH ASSISTANCE after patient has been seen by Plastics. (Do not leave patient alone) Post-op
Nursing Care	
[] Apply warming blanket	Routine, Once Bair Hugger to flap(s) continuously, Post-op
[] Keep room temp at 76 degrees	Routine, Until discontinued, Starting S, Post-op
[] Intake and output	Routine, Per unit protocol, Post-op
[] Foley catheter - discontinue	Routine, Once, Post-op
[] Limb precautions	Location: Precaution: Post-op
[] Bathe patient	Routine, Daily Sponge bath, Post-op
[] Patient may shower with assistance	Routine, Daily Specify: Additional modifier: with assist only Post-op
Do NOT use Hyperglycemia Protocol	Routine, Until discontinued, Starting S, Post-op
[] Electrolyte replacement per SICU protocol	Routine, Until discontinued, Starting S, Post-op
[] Patient education- Post op urine color	Routine, Once Patient/Family: Both Education for: Other (specify) Specify: Blue/green urine post op is normal Post-op
Flap/Incision Care	
[] Apply warming blanket	Routine, Once Bair Hugger to flap(s) continuously; Discontinue on PostOp Day ***, Post-op
[] Drain care	Routine, Until discontinued, Starting S Drain 1: Jackson Pratt Specify location: To bulb suction. Attach bulbs to gown with safety pins. Do NOT tape drains to patient. Drainage/Suction: To Compression (Bulb) Suction Flush drain with: Drain 2: Drain 3: Drain 4: Post-op

[] Drain care	Routine, Every 4 hours Drain 1: Drain 2: Drain 3: Drain 4: All Drains: Strip drain tubing, empty bulb, and record output with all other intake and output values
	Post-op
[] Flap assessment	Routine, Every 15 min
	Side:
	Location: Breast
	Assessment: Check flap(s) for Doppler sound and color every 15 minutes x 2 hours, every 30 minutes x 4 hours, then every hour after that. Have patient pump feet during each doppler check to prevent DVT. Notify resident or physician of flap changes
	ASAP., Post-op
[] Flap assessment	Routine, Every hour Side: Location: Breast Assessment: Post-op
[] Supportive bra	Routine, Until discontinued, Starting S
	Do not remove post operative bra, Post-op
[] Provide equipment / supplies at bedside	Routine, Once
	Supplies:
	Post-op
[] Provide equipment / supplies at bedside: Extra Bra to bedside	Routine, Once Supplies: Other (specify) Other: Extra bra to bedside. Size ***, Post-op
[] Surgical/incision site care	Routine, Once
1, 1, 3, 3, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	Location:
	Site:
	Apply:
	Dressing Type:
	Open to air?
	Do not remove or change surgical dressings., Post-op
[] Wound care orders	Routine, Daily
	Wound care to be performed by:
	Location:
	Site:
	Irrigate wound?
	Apply:
	Dressing Type:
	Post-op
[] Patient education (specify)- Drain care	Routine, Once
	Patient/Family: Both
	Education for: Drain care
	Post-op
Notify	
[] Notify Plastic Surgery resident on-call and Plastics Attending Surgeon for ANY questions regarding the flap or change in flap assessment	Routine, Until discontinued, Starting S, Notify Plastic Surgery resident on-call and Plastics Attending Surgeon for ANY questions regarding the flap or change in flap assessment, Post-op
Notify Plastics Attending for approval prior to	Routine, Until discontinued, Starting S, Post-op
administering vasopressors or diuretic medications	
Notify Physician for any concerns	Routine, Until discontinued, Starting S, Post-op
District Alexander of any concerns	reading, onto discontinuou, otaling 0,1 0st-op

Diet		
] NPO	Diet effective now, Starting S NPO:	
	Pre-Operative fasting options:	
	Post-op	
] NPO except ice chips	Diet effective now, Starting S	
1 The development of the	NPO: Except Ice chips	
	Pre-Operative fasting options:	
	Post-op	
[] Diet- Clear Liquids	Diet effective now, Starting S	
	Diet(s): Clear Liquids	
	Advance Diet as Tolerated?	
	IDDSI Liquid Consistency:	
	Fluid Restriction:	
	Foods to Avoid: Caffeine	
Diet Clearlingide odgenes es televated to Decider	Post-op	
[] Diet-Clear liquids advance as tolerated to Regular	Diet effective now, Starting S Diet(s): Clear Liquids	
	Advance Diet as Tolerated? Yes	
	Target Diet: Regular	
	Advance target diet criteria:	
	IDDSI Liquid Consistency:	
	Fluid Restriction:	
	Foods to Avoid:	
	Post-op	
[] Diet-Soft	Diet effective now, Starting S	
•	Diet(s): GI Soft/Low Residue/Fiber	
	Advance Diet as Tolerated?	
	IDDSI Liquid Consistency:	
	Fluid Restriction:	
	Foods to Avoid: Caffeine	
	Post-op	
[] Diet: Regular	Diet effective now, Starting S	
	Diet(s): Regular	
	Advance Diet as Tolerated?	
	IDDSI Liquid Consistency: Fluid Restriction:	
	Fluid Restriction: Foods to Avoid:	
	Post-op	
	. 55. op	
IV Fluids		

## **IV Fluids**

[]	dextrose 5 % and sodium chloride 0.45 % with potassium chloride 20 mEq/L infusion	125 mL/hr, intravenous, continuous, Post-op
	lactated Ringer's infusion	125 mL/hr, intravenous, continuous, Post-op
[]	sodium chloride 0.9 % infusion	125 mL/hr, intravenous, continuous, Post-op
[]	sodium chloride 0.9 % with potassium chloride 20 mEq/L infusion	125 mL/hr, intravenous, continuous, Post-op
[]	sodium chloride 0.45 % with potassium chloride 20 mEq/L infusion	125 mL/hr, intravenous, continuous, Post-op

## Medications

Reminder: If you need to place orders for PCA Analgesia, after using this order set go to the Order Set Activity and access the General Patient Controlled Analgesia (PCA) Therapy for Opioid Naive Patients (or Tolerant Patients if appropriate).

**Pharmacy Consult** 

[] Pharmacy consult to manage dosing of medicatio	n STAT, Until discontinued, Starting S Which drug do you need help dosing? Contact Number:			
IV Antibiotics: For Patients LESS than or EQUAL to 120 kg				
[] ampicillin-sulbactam (UNASYN) IV	3 g, intravenous, every 6 hours, Post-op Reason for Therapy: Surgical Prophylaxis			
[] cefazolin (ANCEF) IV - For Patients LESS than of EQUAL to 120 kg				
[] cefepime (MAXIPIME) IV - For antipseudomonal coverage	1 g, intravenous, every 8 hours, Post-op Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
[] clindamycin (CLEOCIN) IV	900 mg, intravenous, for 30 Minutes, every 8 hours, Post-op Use if patient penicillin allergic. Reason for Therapy: Surgical Prophylaxis			
[] vancomycin IV plus Optional Pharmacy Consult to Vancomycin	o Dose			
[] vancomycin (VANCOCIN)	15 mg/kg, intravenous, Post-op Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
[] Pharmacy consult to manage vancomycin	STAT, Until discontinued, Starting S Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
IV Antibiotics: For Patients GREATER than 120 kg	I			
[] ampicillin-sulbactam (UNASYN) IV	3 g, intravenous, every 6 hours, Post-op Reason for Therapy: Surgical Prophylaxis			
[] cefazolin (ANCEF) IV - For Patients GREATER the kg	nan 120 3 g, intravenous, every 8 hours, Post-op Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
[] cefepime (MAXIPIME) IV - For antipseudomonal coverage	2 g, intravenous, every 8 hours, Post-op Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
[] clindamycin (CLEOCIN) IV	900 mg, intravenous, for 30 Minutes, every 8 hours, Post-op Use if patient penicillin allergic. Reason for Therapy: Surgical Prophylaxis			
[] vancomycin IV plus Optional Pharmacy Consult to Vancomycin				
[] vancomycin (VANCOCIN)	15 mg/kg, intravenous, Post-op Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
[] Pharmacy consult to manage vancomycin	STAT, Until discontinued, Starting S Reason for Therapy: Surgical Prophylaxis Surgical Prophylaxis:			
Oral Antibiotics				
[] amoxicillin-pot clavulanate (AUGMENTIN) 875-12 per tablet	5 mg 1 tablet, oral, 2 times daily, Post-op Reason for Therapy: Surgical Prophylaxis			
[] cephalexin (KEFLEX) capsule	500 mg, oral, every 8 hours, Post-op Reason for Therapy: Surgical Prophylaxis			
[] clindamycin (CLEOCIN) capsule	450 mg, oral, 4 times daily, Post-op Use if patient is penicillin allergic. Reason for Therapy: Surgical Prophylaxis			
[] minocycline (MINOCIN, DYNACIN) capsule	100 mg, oral, every 12 hours, Post-op Reason for Therapy: Surgical Prophylaxis			
sulfamethoxazole-trimethoprim (BACTRIM DS) 80 mg tablet				

] bacitracin ointment	Topical, 3 times daily, Post-op
	Apply to drain site.
[] bacitracin-polymyxin B (POLYSPORIN) ointment	
: 1	Apply to drain site.
[] neomycin-bacitracin-polymyxinB (NEOSPORIN)	Topical, 3 times daily, Post-op
ointment  mupirocin (BACTROBAN) 2 % ointment	Apply to drain site.
] mupirocin (BACTROBAN) 2 % ointment	Topical, 3 times daily, Post-op Apply to drain site.
] povidone-iodine (BETADINE) ointment	Topical, 3 times daily, Post-op
1 povidone-lodine (BE IADINE) offitherit	Apply to drain site.
Anxiolytics	
] LORazepam (ATIVAN) Oral or IV	"Or" Linked Panel
[] LORazepam (ATIVAN) tablet	1 mg, oral, every 6 hours PRN, anxiety, Post-op
	Give the tablet if the patient can tolerate oral medication. Indication(s): Anxiety
[] LORazepam (ATIVAN) injection	1 mg, intravenous, every 6 hours PRN, anxiety, Post-op
, , ,	Give if unable to take oral OR symptoms inadequately controlled on or
	medication.
	Indication(s): Anxiety
Muscle Spasms (Single Response) Caution: muscle relaxants should be minimized in	
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet  ( ) methocarbamol (ROBAXIN) tablet	·
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet  ( ) methocarbamol (ROBAXIN) tablet  Muscle Pain	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet  ( ) methocarbamol (ROBAXIN) tablet	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-o
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet  ( ) methocarbamol (ROBAXIN) tablet  Muscle Pain	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-ol Indication(s): Other
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet  ( ) methocarbamol (ROBAXIN) tablet  Muscle Pain	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-o
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet  ( ) methocarbamol (ROBAXIN) tablet  Muscle Pain	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-ol Indication(s): Other
Caution: muscle relaxants should be minimized in    ( ) cyclobenzaprine (FLEXERIL) tablet ( ) methocarbamol (ROBAXIN) tablet  Muscle Pain  [ ] diazepam (VALIUM) tablet	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-ol Indication(s): Other Specify: Muscle Pain
Caution: muscle relaxants should be minimized in Caution: muscle relaxants should be minimized in Caution: muscle () cyclobenzaprine (FLEXERIL) tablet () methocarbamol (ROBAXIN) tablet  Muscle Pain () diazepam (VALIUM) tablet  On-Q Pump (Single Response)	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  270 mL, infiltration, continuous, Post-op Regional Block:
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet () methocarbamol (ROBAXIN) tablet  Muscle Pain [] diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for One	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  1 270 mL, infiltration, continuous, Post-op Regional Block: Location:
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet () methocarbamol (ROBAXIN) tablet  Muscle Pain [] diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for One	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op  5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  1-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter:
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet () methocarbamol (ROBAXIN) tablet  Muscle Pain [] diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for One	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op  5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  1-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet () methocarbamol (ROBAXIN) tablet  Muscle Pain () diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for One Pump	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op  5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  n-Q  270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr Bolus Dose (Optional):
Caution: muscle relaxants should be minimized in Caution: muscle relaxants should be minimized in Caution: muscle Pair () methocarbamol (ROBAXIN) tablet  Muscle Pair () diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for Or Pump	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op  5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr Bolus Dose (Optional): n-Q 270 mL, infiltration, continuous, Post-op
Caution: muscle relaxants should be minimized in a cyclobenzaprine (FLEXERIL) tablet () methocarbamol (ROBAXIN) tablet  Muscle Pain () diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for One Pump	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr Bolus Dose (Optional): n-Q 270 mL, infiltration, continuous, Post-op Regional Block:
Caution: muscle relaxants should be minimized in Caution: muscle relaxants should be minimized in Caution: muscle Pair () methocarbamol (ROBAXIN) tablet  Muscle Pair () diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for Or Pump	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-ol Indication(s): Other Specify: Muscle Pain  n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr Bolus Dose (Optional): n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location:
Caution: muscle relaxants should be minimized in Caution: muscle relaxants should be minimized in Caution: muscle Pair () methocarbamol (ROBAXIN) tablet  Muscle Pair () diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for Or Pump	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op 5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-olindication(s): Other Specify: Muscle Pain  n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr Bolus Dose (Optional): n-Q 270 mL, infiltration, continuous, Post-op Regional Block:
Caution: muscle relaxants should be minimized in Caution: muscle relaxants should be minimized in Caution: muscle Pair () methocarbamol (ROBAXIN) tablet  Muscle Pair () diazepam (VALIUM) tablet  On-Q Pump (Single Response) () ropivacaine 0.2% (PF) (NAROPIN) solution for Or Pump	5 mg, oral, every 8 hours PRN, muscle spasms, Post-op 500 mg, oral, 3 times daily PRN, muscle spasms, Post-op  5 mg, oral, every 6 hours PRN, anxiety, muscle pain, Post-ol Indication(s): Other Specify: Muscle Pain  n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter: Continuous Rate: 6 mL/hr Bolus Dose (Optional): n-Q 270 mL, infiltration, continuous, Post-op Regional Block: Location: Catheter:

	morPHINE 30 mg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 1 mg Lockout Interval: Not Ordered Basal Rate: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE.
[]	Vital signs - T/P/R/BP	Adjust doses for age, renal function or other factors.  Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.

[]	hydromorPHONE (DILAUDID) 15 mg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 0.2 mg Lockout: Not Ordered Basal Rate: 0 mg/hr MAX (Four hour dose limit): 3
		mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12
		per minute or more and POSS level of 2 or less. If more than 2 bolus
		doses in 12 hours or if pain persists after increase in demand dose, call
		ordering prescriber. For breakthrough pain in patients ages 19-59 years
		old with normal renal function, may bolus {Bolus Dose: 26662::"0.2"} mg every {Bolus Frequency: 26663::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose: 26664::"0.1"} mg ONCE.
		Adjust doses for age, renal function or other factors.
		Turn Off PCA Continuous Dose (Basal Rate) On Date:
		Turn Off PCA Continuous Dose (Basal Rate) At Time:
[]	Vital signs - T/P/R/BP	Routine, Per unit protocol
	-	- Initially and every 30 minutes for 1 hour after PCA started, bolus
		administration or dose change; then
		- Every hour x 2 starting second hour after PCA started, bolus
		administered or dose change; then
		- Every 4 hours until PCA therapy is discontinued.
	Disharand suitation and tion and	- Immediately following PCA administration tubing change, Post-op
[]	Richmond agitation sedation scale	Routine, Once Hold infusion daily at:
		Target RASS:
		BIS Monitoring (Target BIS: 40-60):
		60 minutes after administration of pain medication AND every 4 hours.
		Assess and document side effects of at least every 4 hours for duration of
		therapy and when patient complains of pain and/or side effects., Post-op
[]	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason
		- Inadequate analgesia
		- Prior to administration of any other narcotics, antiemetics, or sedatives
		other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or
"	physician and/or CERT team for any of the	less
	following:	- Severe and/or recent confusion or disorientation
	S .	- POSS sedation level 4: Somnolent and difficult to arouse
		- Sustained hypotension (SBP less than 90)
		- Excessive nausea or vomiting
_		- Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to
		arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4
		mg). If naloxone is needed, please call the ordering physician and/or
		CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15
		minutes for 3 times.
() fe	entaNYL PCA (SUBLIMAZE) 1500 mcg/30 mL	

[] fentaNYL (SUBLIMAZE) 1500 mcg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 10 mcg Lockout: Not Ordered Basal Rate: 0 mcg/hr Four Hour Dose Limit: 150 mcg intravenous, continuous, Post-op **Due to fentaNYL 600 mcg/30 mL shortages, the new standard for all facilities will be fentaNYL 1500 mcg/30 mL. This concentration is 2.5 x more concentrated.**
	Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency: 26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors.  Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
[] Vital signs - T/P/R/BP	Routine, Per unit protocol  - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then  - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then  - Every 4 hours until PCA therapy is discontinued.  - Immediately following PCA administration tubing change, Post-op
[] Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[] Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[] Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[] naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
PCA Medications (Single Response)	
() morPHINE PCA 30 mg/30 mL	

[]	morPHINE 30 mg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 1 mg Lockout Interval: Not Ordered Basal Rate: 0 mg/hr MAX (Four hour dose limit): 20 mg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patients ages 19-59 years old with normal renal function, may bolus {Bolus Dose:26657::"2"} mg every {Bolus Frequency:26659::"3"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26660::"0.5"} mg ONCE.
[]	Vital signs - T/P/R/BP	Adjust doses for age, renal function or other factors.  Routine, Per unit protocol  Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then  Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then  Every 4 hours until PCA therapy is discontinued.  Immediately following PCA administration tubing change, Post-op
	Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
	Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[]	Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[]	naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg ydromorPHONE PCA (DILAUDID) 15 mg/30 m	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.

[] hydromorPHONE (DILAUDID) 15 mg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 0.2 mg Lockout Not Ordered Basal Rate: 0 mg/hr MAX (Four hour dose limit): 3 mg intravenous, continuous, Post-op
	Management of breakthrough pain. Administer only if respiratory rate 12
	per minute or more and POSS level of 2 or less. If more than 2 bolus
	doses in 12 hours or if pain persists after increase in demand dose, call
	ordering prescriber. For breakthrough pain in patients ages 19-59 years
	old with normal renal function, may bolus {Bolus Dose: 26662::"0.2"} mg
	every {Bolus Frequency:26663::"3"} hours as needed. If pain persists,
	may increase PCA demand dose by {PCA Dose:26664::"0.1"} mg ONCE
	Adjust doses for age, renal function or other factors.
	Turn Off PCA Continuous Dose (Basal Rate) On Date:
	Turn Off PCA Continuous Dose (Basal Rate) At Time:
[] Vital signs - T/P/R/BP	Routine, Per unit protocol
	<ul> <li>Initially and every 30 minutes for 1 hour after PCA started, bolus</li> </ul>
	administration or dose change; then
	<ul> <li>Every hour x 2 starting second hour after PCA started, bolus</li> </ul>
	administered or dose change; then
	- Every 4 hours until PCA therapy is discontinued.
	- Immediately following PCA administration tubing change, Post-op
[] Richmond agitation sedation sca	
	Hold infusion daily at:
	Target RASS:
	BIS Monitoring (Target BIS: 40-60):
	60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of
	therapy and when patient complains of pain and/or side effects., Post-op
Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued
[] Noth y i flysician (Opeony)	for any reason
	- Inadequate analgesia
	- Prior to administration of any other narcotics, antiemetics, or sedatives
	other than those ordered by the prescriber responsible for IV PCA therap
	- PCA pump discontinued by any service other than the prescriber
	responsible for IV PCA therapy, Post-op
[] Stop the PCA pump and call ord	
physician and/or CERT team for	·
following:	<ul> <li>Severe and/or recent confusion or disorientation</li> </ul>
	- POSS sedation level 4: Somnolent and difficult to arouse
	- Sustained hypotension (SBP less than 90)
	- Excessive nausea or vomiting
[] (NADOANI) O.4. / I	- Urinary retention, Post-op
[] naloxone (NARCAN) 0.4 mg/mL	
0.2 mg	respiratory rate 8 per minute or less OR patient somnolent and difficult to
	arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4
	mg). If naloxone is needed, please call the ordering physician and/or
	CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15
	minutes for 3 times.
) fentaNYL PCA (SUBLIMAZE) 600 r	***************************************
, 13.11411 L 1 3/1 (335 L 11VIAZE) 000 1	nogroo me

[] fentaNYL (SUBLIMAZE) 600 mcg/30 mL PCA	Nurse Loading Dose: Not Ordered PCA Dose: 10 mcg Lockout Interval: Not Ordered Basal Rate: 0 mcg/hr MAX (Four hour dose limit): 150 mcg intravenous, continuous, Post-op Management of breakthrough pain. Administer only if respiratory rate 12 per minute or more and POSS level of 2 or less. If more than 2 bolus doses in 12 hours or if pain persists after increase in demand dose, call ordering prescriber. For breakthrough pain in patient 19-59 years old, may bolus {Bolus Dose:26656::"25"} mcg every {Bolus Frequency:26655::"2"} hours as needed. If pain persists, may increase PCA demand dose by {PCA Dose:26654::"10"} mcg ONCE. Adjust doses for age, renal function or other factors.
	Turn Off PCA Continuous Dose (Basal Rate) On Date: Turn Off PCA Continuous Dose (Basal Rate) At Time:
[] Vital signs - T/P/R/BP	Routine, Per unit protocol - Initially and every 30 minutes for 1 hour after PCA started, bolus administration or dose change; then - Every hour x 2 starting second hour after PCA started, bolus administered or dose change; then - Every 4 hours until PCA therapy is discontinued Immediately following PCA administration tubing change, Post-op
[] Richmond agitation sedation scale	Routine, Once Hold infusion daily at: Target RASS: BIS Monitoring (Target BIS: 40-60): 60 minutes after administration of pain medication AND every 4 hours. Assess and document side effects of at least every 4 hours for duration of therapy and when patient complains of pain and/or side effects., Post-op
[] Notify Physician (Specify)	Routine, Until discontinued, Starting S, - PCA pump infusion discontinued for any reason - Inadequate analgesia - Prior to administration of any other narcotics, antiemetics, or sedatives other than those ordered by the prescriber responsible for IV PCA therapy - PCA pump discontinued by any service other than the prescriber responsible for IV PCA therapy, Post-op
[] Stop the PCA pump and call ordering physician and/or CERT team for any of the following:	Routine, Until discontinued, Starting S, - Respiratory rate 10 per minute or less - Severe and/or recent confusion or disorientation - POSS sedation level 4: Somnolent and difficult to arouse - Sustained hypotension (SBP less than 90) - Excessive nausea or vomiting - Urinary retention, Post-op
[] naloxone (NARCAN) 0.4 mg/mL injection 0.2 mg	0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
Mild Pain (Pain Score 1-3) or Fever	
[] acetaminophen (TYLENOL) tablet	650 mg, oral, every 6 hours PRN, mild pain (score 1-3), fever, Post-op Contact physician for fever GREATER than 101 F
Oral for Moderate Pain (Pain Score 4-6) (Single R	esponse)
( ) HYDROcodone-acetaminophen (NORCO) 5-325 tablet	5 mg per 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op Give if patient is able to tolerate oral medication

( ) morPHINE injection  ( ) hydromorPHONE (DILAUDID) injection  Respiratory  [X] naloxone (NARCAN) injection  Bowel Care - NOT HMSJ  [] docusate sodium (COLACE) capsule	2 mg, intravenous, every 4 hours PRN, severe pain (score 7-10), Post-op Give if patient cannot tolerate oral medications or a faster onset of action is required.  0.2 mg, intravenous, every 4 hours PRN, severe pain (score 7-10), Post-op Use if patient is unable to swallow or faster onset is needed  0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg). If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
( ) hydromorPHONE (DILAUDID) injection  Respiratory  [X] naloxone (NARCAN) injection  Bowel Care - NOT HMSJ	7-10), Post-op Give if patient cannot tolerate oral medications or a faster onset of action is required.  0.2 mg, intravenous, every 4 hours PRN, severe pain (score 7-10), Post-op Use if patient is unable to swallow or faster onset is needed  0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg).  If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3 times.
( ) hydromorPHONE (DILAUDID) injection  Respiratory	7-10), Post-op Give if patient cannot tolerate oral medications or a faster onset of action is required.  0.2 mg, intravenous, every 4 hours PRN, severe pain (score 7-10), Post-op Use if patient is unable to swallow or faster onset is needed  0.2 mg, intravenous, once PRN, respiratory depression, as needed for respiratory rate 8 per minute or less OR patient somnolent and difficult to arouse (POSS GREATER than 3)., Post-op Repeat Naloxone 0.2 mg once in 2 minutes if necessary (MAXIMUM 0.4 mg).  If naloxone is needed, please call the ordering physician and/or CERT team. Monitor vital signs (pulse oximetry, P/R/BP) every 15 minutes for 3
	O many instruction accounts A become DDNL account in in /a account
( ) oxyCODone-acetaminophen (PERCOCET) 10-325 mg per tablet  IV for Severe Pain (Pain Score 7-10) (Single Response)     If you select a PCA option you will not be allowed to also orce.	·
( ) traMADol (ULTRAM) tablet	100 mg, oral, every 6 hours PRN, severe pain (score 7-10), Post-op
Oral for Severe Pain (Pain Score 7-10) (Single Response)  () HYDROcodone-acetaminophen (NORCO 10-325) 10-325 mg per tablet	1 tablet, oral, every 4 hours PRN, severe pain (score 7-10), Post-op Give if patient is able to tolerate oral medication
() morPHINE injection	1 mg, intravenous, every 4 hours PRN, moderate pain (score 4-6), Post-op Give if patient cannot tolerate oral medications or a faster onset of action is required.
IV for Moderate Pain (Pain Score 4-6) (Single Response) If you select a PCA option you will not be allowed to also ord	Post-op Give if patient is able to tolerate oral medication  ler IV PRN pain medications from this section.
( ) oxyCODONE-acetaminophen (PERCOCET) 5-325 mg	Give if patient is able to tolerate oral medication  1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6),
( ) avu/CODONE aastaminanhan (DEDCOCET) 5 225 mg	Post-op
( ) traMADol (ULTRAM) tablet	Give if patient is able to tolerate oral medication 50 mg, oral, every 6 hours PRN, moderate pain (score 4-6),

[] bisacodyl (DULCOLAX) suppository	10 mg, rectal, daily PRN, constipation, Post-op Suppository can be used if oral therapy is not tolerated or ineffective.
[] senna (SENOKOT) tablet	1 tablet, oral, 2 times daily PRN, constipation, Post-op
[] diphenoxylate-atropine (LOMOTIL) 2.5-0.025 mg tablet	per 1 tablet, oral, 4 times daily PRN, diarrhea, Post-op
Antiemetics - HMSL, HMWB Only	
[X] ondansetron (ZOFRAN) IV or Oral (Selection Re	•
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) IV or Oral or Rect	
[X] promethazine (PHENERGAN) 12.5 mg in sodium chloride 0.9 % 0.9 % 20 mL for	12.5 mg, intravenous, at 60 mL/hr, for 20 Minutes, every 6 hours PRN, nausea, vomiting, Post-op
Alaris pump syringe option	Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[X] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
Antiemetics - HMH, HMSJ, HMW, HMSTC, HMTW	
[X] ondansetron (ZOFRAN) IV or Oral (Selection Re	
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) IV or Oral or Rect	al "Or" Linked Panel
[X] promethazine (PHENERGAN) 12.5 mg IV	12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerate oral medication.
[X] promethazine (PHENERGAN) suppository	12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
Antiemetics - HMSTJ Only	
[X] ondansetron (ZOFRAN) IV or Oral (Selection Re	•
[X] ondansetron ODT (ZOFRAN-ODT) disintegrating tablet	4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is able to tolerate oral medication.
[X] ondansetron (ZOFRAN) 4 mg/2 mL injection	4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.
[X] promethazine (PHENERGAN) IVPB or Oral or R	
[X] promethazine (PHENERGAN) 25 mg in sodium chloride 0.9 % 50 mL IVPB	12.5 mg, intravenous, for 30 Minutes, every 6 hours PRN, nausea, vomiting, Post-op
	Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required.

[X] promethazine (PHENERGAN) tablet	12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is able to tolerat
[X] promethazine (PHENERGAN) suppository	oral medication.  12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op Give if ondansetron (ZOFRAN) is ineffective and patient is UNable to tolerate oral medication.
Itching: For Patients GREATER than 77 years old	· · · · · · · · · · · · · · · · · ·
( ) cetirizine (ZyrTEC) tablet	5 mg, oral, daily PRN, itching, Post-op
Itching: For Patients between 70-76 years old (S	ingle Response)
( ) cetirizine (ZyrTEC) tablet	5 mg, oral, daily PRN, itching, Post-op
Itching: For Patients LESS than 70 years old (Sir	ngle Response)
( ) diphenhydrAMINE (BENADRYL) tablet	25 mg, oral, every 6 hours PRN, itching, Post-op
( ) hydrOXYzine (ATARAX) tablet	10 mg, oral, every 6 hours PRN, itching, Post-op
( ) cetirizine (ZyrTEC) tablet	5 mg, oral, daily PRN, itching, Post-op
() fexofenadine (ALLEGRA) tablet - For eGFR LES	
80 mL/min, reduce frequency to once daily as ne	
Insomnia: For Patients GREATER than 70 years	old (Single Response)
( ) ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep, Post-op
Insomnia: For Patients LESS than 70 years old (	Single Response)
( ) zolpidem (AMBIEN) tablet	5 mg, oral, nightly PRN, sleep, Post-op
( ) ramelteon (ROZEREM) tablet	8 mg, oral, nightly PRN, sleep, Post-op
VTE	
	(Selection Deguired)
DVT Risk and Prophylaxis Tool (Single Respons VTE/DVT Risk Definitions	URL:
VIE/DVIINSK Deminions	"\\appt1\epicappprod\Restricted\OrderSets\VTEDVTRISK
	DEFINITIONS.pdf"
Anticoagulation Guide for COVID patients	URL:
Anticoagulation odide for oovid patients	"https://formweb.com/files/houstonmethodist/documents/C
	OVID-19 Anticoagulation Guideline - 8.20.2021v15.pdf"
() Patient currently has an active order for therape	
anticoagulant or VTE prophylaxis with Risk Strat (Single Response) (Selection Required)	tification
() Moderate Risk - Patient currently has an activ	ve order for
therapeutic anticoagulant or VTE prophylaxis	
Required)	
Moderate risk of VTE	Routine, Once, PACU & Post-op
[] Patient currently has an active order for	Routine, Once
therapeutic anticoagulant or VTE	No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
propriyatio	Therapy for the following:
	PACU & Post-op
[] Place sequential compression device (Single	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following
p.0p.13.0000	contraindication(s):
	PACU & Post-op
/	
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op

() Moderate Risk - Patient currently has an active therapeutic anticoagulant or VTE prophylaxis (\$\frac{1}{2}\text{S} = \frac{1}{2}\text{S} = \frac{1}{2}\	
Required)	D (' O DAOHAD (
Moderate risk of VTE	Routine, Once, PACU & Post-op
[] Patient currently has an active order for	Routine, Once
therapeutic anticoagulant or VTE	No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
	Therapy for the following: PACU & Post-op
Place sequential compression device (Single	
Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following
propriyiaxis	contraindication(s):
	PACU & Post-op
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous  ( ) High Risk - Patient currently has an active orde	or for
therapeutic anticoagulant or VTE prophylaxis (\$	
Required)	Delection
High risk of VTE	Routine, Once, PACU & Post-op
Patient currently has an active order for	Routine, Once
therapeutic anticoagulant or VTE	No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
1 -1 7	Therapy for the following:
	PACU & Post-op
[] Place sequential compression device (Single I	Response)
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following
	contraindication(s):
	PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() High Risk - Patient currently has an active order	
therapeutic anticoagulant or VTE prophylaxis (\$	Selection
Required)	D. I. O. DAGUAD
[] High risk of VTE	Routine, Once, PACU & Post-op
[] Patient currently has an active order for	Routine, Once
therapeutic anticoagulant or VTE	No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
	Therapy for the following:
Place sequential compression device (Single	PACU & Post-op
· · · · · · · · · · · · · · · · · · ·	Routine, Once
() Contraindications exist for mechanical prophylaxis	No mechanical VTE prophylaxis due to the following
propriyiaxis	contraindication(s):
	PACU & Post-op
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous	reduine, continuous, i rice a i est op
) LOW Risk of DVT (Selection Required)	
Low Risk Definition	
Age less than 60 years and NO other VTE risk fac	etors
,	
[] Low Risk (Single Response) (Selection Require	
() Low risk of VTE	Routine, Once
	Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae
	early ambulation
) MODERATE Dialy -4 DVT On 1 1/0 1 // D	PACU & Post-op
) MODERATE Risk of DVT - Surgical (Selection Re	ANICEA)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once, PACU & Post-op
[] Moderate Risk Pharmacological Prophylaxis - S	
Patient (Single Response) (Selection Required)	
<ul> <li>() Contraindications exist for pharmacologic prop BUT order Sequential compression device</li> </ul>	ohylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
<ul> <li>( ) Contraindications exist for pharmacologic prop AND mechanical prophylaxis</li> </ul>	hylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
[ ] Contraindications exist for mechanical	PACU & Post-op  Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following
propriyiaxis	contraindication(s):
	PACU & Post-op
( ) enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	ponse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op For Patients with CrCL LESS than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1, PACU & Post-op
	For Patients weight between 100-139 kg and CrCl GREATER than 30
	mL/min
	Indication(s): VTE Prophylaxis
<ul><li>() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min</li></ul>	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1, PACU & Post-op
	For Patients weight 140 kg or GREATER and CrCl GREATER than 30
	mL/min
	Indication(s): VTE Prophylaxis

() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g.	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients	7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU &
with weight GREATER than 100 kg	Post-op
	For patients with weight GREATER than 100 kg.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
<ul><li>[] Mechanical Prophylaxis (Single Response) (Se Required)</li></ul>	election
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous	
MODERATE Risk of DVT - Non-Surgical (Selection	on
Required)	
Moderate Risk Definition	

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once, PACU & Post-op
<ul> <li>[] Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Selecti Required)</li> </ul>	on
( ) Contraindications exist for pharmacologic prople Order Sequential compression device	hylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() Contraindications exist for pharmacologic prop	hylaxis "And" Linked Panel

AND mechanical prophylaxis

[]	Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[]	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
	enoxaparin (LOVENOX) injection (Single Res (Selection Required)	ponse)
()	enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis
()	patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S+1, PACU & Post-op For Patients with CrCL LESS than 30 mL/min Indication(s): VTE Prophylaxis
()	patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100, Starting S+1, PACU & Post-op For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
()	patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, every 12 hours at 0900, 2100, Starting S+1, PACU & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 3 mL/min Indication(s): VTE Prophylaxis
()	fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
()	heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
` '	heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LES than 50kg and age GREATER than 75yrs.
()	HEParin (porcine) injection - For Patients with weight GREATER than 100 kg	7,500 Units, subcutaneous, every 8 hours, PACU & Post-op For patients with weight GREATER than 100 kg.
	warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
	Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
-	/lechanical Prophylaxis (Single Response) (Se Required)	election
()	Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s PACU & Post-op
	Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
High Risk Pharmacological Prophylaxis - Surg	
(Single Response) (Selection Required)	
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
() =	PACU & Post-op
( ) Enoxaparin for VTE Prophylaxis (Single Resp	
() enoxaparin (LOVENOX) 30 mg Daily at 170	
[] enoxaparin (LOVENOX) injection	30 mg, subcutaneous, daily at 1700 Indication(s):
( ) enoxaparin (LOVENOX) 30 mg Every 12 Ho	
[] enoxaparin (LOVENOX) injection	30 mg, subcutaneous, daily at 1700
[] elloxapaliii (LOV ENOX) iiijectioii	Indication(s):
() enoxaparin (LOVENOX) 40 mg Daily at 170	
<ul><li>enoxaparin (LOVENOX) injection</li></ul>	40 mg, subcutaneous, daily at 1700
	Indication(s):
() enoxaparin (LOVENOX) 40 mg Every 12 Ho	
[] enoxaparin (LOVENOX) injection	40 mg, subcutaneous, every 12 hours Indication(s):
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op
	If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.  This patient has a history of or suspected case of Heparin-Induced
	Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU &
() (	Post-op
() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU &
for patients with high risk of bleeding, e.g.	Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients	7,500 Units, subcutaneous, every 8 hours, Starting S+1, PACU &
with weight GREATER than 100 kg	Post-op
	For patients with weight GREATER than 100 kg.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Se Required)	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s):
	PACU & Post-op

( ) Place/Maintain sequential compression Routine, Continuous, PACU & Post-op device continuous

() HIGH Risk of DVT - Non-Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

<ul><li>High Risk (Selection Required)</li><li>High risk of VTE</li></ul>	Routine, Once, PACU & Post-op
<ul> <li>High Risk Pharmacological Prophylaxis - Non-S Patient (Single Response) (Selection Required)</li> </ul>	
( ) Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
( ) enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	ponse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S, PACU & Post-op Indication(s): VTE Prophylaxis
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S, PACU & Post-op For Patients with CrCL LESS than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S, PACU & Post-op For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S, PACU & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
<ul><li>( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li></ul>	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) HEParin (porcine) injection - For Patients with weight GREATER than 100 kg	7,500 Units, subcutaneous, every 8 hours, PACU & Post-op For patients with weight GREATER than 100 kg.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

Required)

	()	Contraindications exist for mechanical	Routine, Once
		prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s):
			PACU & Post-op
	()	Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
	( )	device continuous	
()	HIC	GH Risk of DVT - Surgical (Hip/Knee) (Selection	
٠,	_		

Required)
High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	Davider Orac DAOH 9 Davider
[] High risk of VTE	Routine, Once, PACU & Post-op
<ul><li>[] High Risk Pharmacological Prophylaxis - Hip of (Arthroplasty) Surgical Patient (Single Respon</li></ul>	
(Selection Required)	56)
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
F. o.F. Marine	contraindication(s):
	PACU & Post-op
() aspirin chewable tablet	162 mg, oral, daily, Starting S+1, PACU & Post-op
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1, PACU & Post-op
() Apixaban and Pharmacy Consult (Selection F	Required)
[] apixaban (ELIQUIS) tablet	2.5 mg, oral, 2 times daily, Starting S+1, PACU & Post-op
	Indications: VTE prophylaxis
[] Pharmacy consult to monitor apixaban	STAT, Until discontinued, Starting S
(ELIQUIS) therapy	Indications: VTE prophylaxis
( ) enoxaparin (LOVENOX) injection (Single Res (Selection Required)	
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op
	Indication(s): VTE Prophylaxis
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL),
	Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis
( ) enoxaparin (LOVENOX) syringe - For	30 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op
Patients with CrCL LESS than 30 mL/min	For Patients with CrCL LESS than 30 mL/min.
	Indication(s): VTE Prophylaxis
( ) enoxaparin (LOVENOX) syringe - For	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL),
Patients weight between 100-139 kg and	Starting S+1, PACU & Post-op
CrCl GREATER than 30 mL/min	For Patients weight between 100-139 kg and CrCl GREATER than 30
	mL/min.
() : (I O) (ENO)() : E	Indication(s): VTE Prophylaxis
( ) enoxaparin (LOVENOX) syringe - For	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL),
Patients weight between 140 kg or GREATER and CrCl GREATER than 30	Starting S+1, PACU & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 30
mL/min	mL/min
<u>.</u>	Indication(s): VTE Prophylaxis

() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients with weight GREATER than 100 kg	7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op For patients with weight GREATER than 100 kg.
() Rivaroxaban and Pharmacy Consult (Selection Required)	
<ul><li>[] rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission</li></ul>	10 mg, oral, daily at 0600 (TIME CRITICAL), PACU & Post-op Indications: VTE prophylaxis
[] Pharmacy consult to monitor rivaroxaban (XARELTO) therapy	STAT, Until discontinued, Starting S Indications: VTE prophylaxis
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Sel Required)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
DVT Risk and Prophylaxis Tool (Single Response) VTE/DVT Risk Definitions  Anticoagulation Guide for COVID patients	URL: "\\appt1\epicappprod\Restricted\OrderSets\VTEDVTRISK DEFINITIONS.pdf" URL: "https://formweb.com/files/houstonmethodist/documents/C OVID-19 Anticoagulation Guideline - 8.20.2021v15.pdf"
<ul> <li>( ) Patient currently has an active order for therapeuti anticoagulant or VTE prophylaxis with Risk Stratifi (Single Response) (Selection Required)</li> </ul>	cation
<ul> <li>() Moderate Risk - Patient currently has an active therapeutic anticoagulant or VTE prophylaxis (S Required)</li> </ul>	
Moderate risk of VTE     Detions ourroutly has an active order for	Routine, Once, PACU & Post-op
<ul> <li>Patient currently has an active order for therapeutic anticoagulant or VTE prophylaxis</li> </ul>	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication. Therapy for the following: PACU & Post-op
[] Place sequential compression device (Single F	
<ul> <li>( ) Contraindications exist for mechanical prophylaxis</li> </ul>	Routine, Once  No mechanical VTE prophylaxis due to the following contraindication(s):  PACU & Post-op

() Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
<ul> <li>Moderate Risk - Patient currently has an active therapeutic anticoagulant or VTE prophylaxis (</li> </ul>	
Required) Moderate risk of VTE	Pouting Once DACIL® Doct on
Noderate risk of VTE     Patient currently has an active order for	Routine, Once, PACU & Post-op
therapeutic anticoagulant or VTE	Routine, Once No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
propriyiaxis	Therapy for the following:
	PACU & Post-op
] Place sequential compression device (Single	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following
1 1 3	contraindication(s):
	PACU & Post-op
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous	·
High Risk - Patient currently has an active ord	
therapeutic anticoagulant or VTE prophylaxis (	Selection
Required)	
] High risk of VTE	Routine, Once, PACU & Post-op
Patient currently has an active order for	Routine, Once
therapeutic anticoagulant or VTE	No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
	Therapy for the following:
7.51	PACU & Post-op
Place sequential compression device (Single	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following
	contraindication(s):
() Place/Maintain sequential compression	PACU & Post-op Routine, Continuous, PACU & Post-op
device continuous	
High Risk - Patient currently has an active ord	
therapeutic anticoagulant or VTE prophylaxis (	Selection
Required)	Davidina Oraca DAOLLO Dest en
High risk of VTE	Routine, Once, PACU & Post-op
Patient currently has an active order for	Routine, Once
therapeutic anticoagulant or VTE	No pharmacologic VTE prophylaxis because: patient is already on
prophylaxis	therapeutic anticoagulation for other indication.
	Therapy for the following: PACU & Post-op
1 Place segmential compression device (Single	
<ul><li>Place sequential compression device (Single</li><li>( ) Contraindications exist for mechanical</li></ul>	
\ /	Routine, Once No mechanical VTE prophylaxis due to the following
prophylaxis	contraindication(s):
	PACU & Post-op
	·
( ) Place/Maintain sequential compression	
	Routine, Continuous, PACU & Post-op
device continuous	Routine, Continuous, PACO & Post-op
OW Risk of DVT (Selection Required)	Routine, Continuous, PACO & Post-op
device continuous  LOW Risk of DVT (Selection Required)  Low Risk Definition	
device continuous  OW Risk of DVT (Selection Required)	

() Low risk of VTE	Routine, Once
.,	Low risk: Due to low risk, no VTE prophylaxis is needed. Will encourgae
	early ambulation
	PACU & Post-op

() MODERATE Risk of DVT - Surgical (Selection Required)

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

[] Moderate Risk (Selection Required)	
[] Moderate risk of VTE	Routine, Once, PACU & Post-op
<ul> <li>[] Moderate Risk Pharmacological Prophylaxis - S Patient (Single Response) (Selection Required)</li> </ul>	
() Contraindications exist for pharmacologic prop BUT order Sequential compression device	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
() Contraindications exist for pharmacologic prop AND mechanical prophylaxis	phylaxis "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	oonse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op For Patients with CrCL LESS than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1, PACL & Post-op For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800, Starting S+1, PACL & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis

( ) fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op
() Torradparriax () tractifut () injoction	If the patient does not have a history of or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced
	Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU &
· · · · · · · · · · · · · · · · · · ·	Post-op
() heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU &
for patients with high risk of bleeding, e.g.	Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS
	than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients	7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU &
with weight GREATER than 100 kg	Post-op
	For patients with weight GREATER than 100 kg.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op
	Indication:
() Pharmacy consult to manage warfarin	STAT, Until discontinued, Starting S
(COUMADIN)	Indication:
] Mechanical Prophylaxis (Single Response) (Se	election
Required)	
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s):
	PACU & Post-op
() Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op
device continuous	
MODERATE Risk of DVT - Non-Surgical (Selection	ion
Required)	
Madarata Diak Definition	

Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated.

One or more of the following medical conditions:

CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Age 60 and above

Central line

History of DVT or family history of VTE

Anticipated length of stay GREATER than 48 hours

Less than fully and independently ambulatory

Estrogen therapy

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Moderate risk of VTE	Routine, Once, PACU & Post-op
Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response) (Select Required)	tion
<ul> <li>Contraindications exist for pharmacologic prop Order Sequential compression device</li> </ul>	ohylaxis - "And" Linked Panel
[] Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
] Place/Maintain sequential compression	Routine, Continuous, PACU & Post-op

AND mechanical prophylaxis

[] Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
[] Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
() enoxaparin (LOVENOX) injection (Single Resp (Selection Required)	
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S+1, PACU & Post-op For Patients with CrCL LESS than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, every 12 hours at 0900, 2100, Starting S+1, PACU & Post-op For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S, PACU & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
() heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients with weight GREATER than 100 kg	7,500 Units, subcutaneous, every 8 hours, PACU & Post-op For patients with weight GREATER than 100 kg.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
( ) Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
<ul><li>[] Mechanical Prophylaxis (Single Response) (Sel Required)</li></ul>	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions: Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)	
[] High risk of VTE	Routine, Once, PACU & Post-op
[] High Risk Pharmacological Prophylaxis - Surg	ical Patient
(Single Response) (Selection Required)	
() Contraindications exist for pharmacologic	Routine, Once
prophylaxis	No pharmacologic VTE prophylaxis due to the following
	contraindication(s):
	PACU & Post-op
( ) Enoxaparin for VTE Prophylaxis (Single Resp	
( ) enoxaparin (LOVENOX) 30 mg Daily at 170	
[] enoxaparin (LOVENOX) injection	30 mg, subcutaneous, daily at 1700
( ) anavanaria (LO) (ENOV) 20 mg Evan (12 Lla	Indication(s):
( ) enoxaparin (LOVENOX) 30 mg Every 12 Ho	
[] enoxaparin (LOVENOX) injection	30 mg, subcutaneous, daily at 1700 Indication(s):
( ) enoxaparin (LOVENOX) 40 mg Daily at 170	· · · · · · · · · · · · · · · · · · ·
[] enoxaparin (LOVENOX) injection	40 mg, subcutaneous, daily at 1700
	Indication(s):
( ) enoxaparin (LOVENOX) 40 mg Every 12 Ho	
[] enoxaparin (LOVENOX) injection	40 mg, subcutaneous, every 12 hours
[] Shexapalin (20 ) and shex	Indication(s):
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op
	If the patient does not have a history or suspected case of
	Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication.
	Contraindicated in patients LESS than 50kg, prior to surgery/invasive
	procedure, or CrCl LESS than 30 mL/min.
	This patient has a history of or suspected case of Heparin-Induced
( ) han arin (n a raina) inication	Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
( ) heparin (porcine) injection (Recommended	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU &
for patients with high risk of bleeding, e.g.	Post-op
weight < 50kg and age > 75yrs)	Recommended for patients with high risk of bleeding, e.g. weight LESS
mongrit 4 bordy and agos 1 by 10,	than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients	7,500 Units, subcutaneous, every 8 hours, Starting S+1, PACU &
with weight GREATER than 100 kg	Post-op
	For patients with weight GREATER than 100 kg.
() warfarin (COUMADIN) tablet	oral, daily at 1700, Starting S+1, PACU & Post-op
	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Se Required)	election
() Contraindications exist for mechanical	Routine, Once
prophylaxis	No mechanical VTE prophylaxis due to the following contraindication(s):
	PACU & Post-op

( ) Place/Maintain sequential compression Routine, Continuous, PACU & Post-op device continuous

() HIGH Risk of DVT - Non-Surgical (Selection Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

History of PE

High Risk (Selection Required)     High risk of VTE	Routine, Once, PACU & Post-op
<ul> <li>High Risk Pharmacological Prophylaxis - Non-S Patient (Single Response) (Selection Required)</li> </ul>	Burgical
( ) Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op
<ul><li>( ) enoxaparin (LOVENOX) injection (Single Resp (Selection Required)</li></ul>	oonse)
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 1700, Starting S, PACU & Post-op Indication(s): VTE Prophylaxis
() patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 1700, Starting S, PACU & Post-op For Patients with CrCL LESS than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight between 100-139 kg AND CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily, Starting S, PACU & Post-op For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() patients weight 140 kg or GREATER AND CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily, Starting S, PACU & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis
() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, PACU & Post-op If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min. This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
() heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, PACU & Post-op
<ul> <li>( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight &lt; 50kg and age &gt; 75yrs)</li> </ul>	5,000 Units, subcutaneous, every 12 hours, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
( ) HEParin (porcine) injection - For Patients with weight GREATER than 100 kg	7,500 Units, subcutaneous, every 8 hours, PACU & Post-op For patients with weight GREATER than 100 kg.
( ) warfarin (COUMADIN) tablet	oral, daily at 1700, PACU & Post-op Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:

Required)

	) Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s):
(	) Place/Maintain sequential compression device continuous	PACU & Post-op Routine, Continuous, PACU & Post-op
() H	IGH Risk of DVT - Surgical (Hip/Knee) (Selection	n

Required)

High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

One or more of the following medical conditions:

Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Severe fracture of hip, pelvis or leg

Acute spinal cord injury with paresis

Multiple major traumas

Abdominal or pelvic surgery for CANCER

Acute ischemic stroke

[] High Risk (Selection Required)		
[] High risk of VTE	Routine, Once, PACU & Post-op	
<ul><li>[] High Risk Pharmacological Prophylaxis - Hip of (Arthroplasty) Surgical Patient (Single Respond (Selection Required)</li></ul>	ise)	
() Contraindications exist for pharmacologic prophylaxis	Routine, Once No pharmacologic VTE prophylaxis due to the following contraindication(s): PACU & Post-op	
( ) aspirin chewable tablet	162 mg, oral, daily, Starting S+1, PACU & Post-op	
() aspirin (ECOTRIN) enteric coated tablet	162 mg, oral, daily, Starting S+1, PACU & Post-op	
( ) Apixaban and Pharmacy Consult (Selection Required)		
[] apixaban (ELIQUIS) tablet	2.5 mg, oral, 2 times daily, Starting S+1, PACU & Post-op Indications: VTE prophylaxis	
[] Pharmacy consult to monitor apixaban (ELIQUIS) therapy	STAT, Until discontinued, Starting S Indications: VTE prophylaxis	
<ul><li>( ) enoxaparin (LOVENOX) injection (Single Res (Selection Required)</li></ul>	sponse)	
( ) enoxaparin (LOVENOX) syringe	40 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis	
() enoxaparin (LOVENOX) syringe	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1, PACU & Post-op Indication(s): VTE Prophylaxis	
( ) enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min	30 mg, subcutaneous, daily at 0600, Starting S+1, PACU & Post-op For Patients with CrCL LESS than 30 mL/min. Indication(s): VTE Prophylaxis	
() enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min	30 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1, PACU & Post-op For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min. Indication(s): VTE Prophylaxis	
() enoxaparin (LOVENOX) syringe - For Patients weight between 140 kg or GREATER and CrCl GREATER than 30 mL/min	40 mg, subcutaneous, 2 times daily at 0600, 1800 (TIME CRITICAL), Starting S+1, PACU & Post-op For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min Indication(s): VTE Prophylaxis	

() fondaparinux (ARIXTRA) injection	2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT):
( ) heparin (porcine) injection	5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op
( ) heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)	5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.
() HEParin (porcine) injection - For Patients with weight GREATER than 100 kg	7,500 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op For patients with weight GREATER than 100 kg.
( ) Rivaroxaban and Pharmacy Consult (Selection Required)	
[] rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission	10 mg, oral, daily at 0600 (TIME CRITICAL), PACU & Post-op Indications: VTE prophylaxis
[] Pharmacy consult to monitor rivaroxaban	STAT, Until discontinued, Starting S
(XARELTO) therapy () warfarin (COUMADIN) tablet	Indications: VTE prophylaxis oral, daily at 1700, Starting S+1, PACU & Post-op
( ) warfarin (COUMADIN) tablet	Indication:
() Pharmacy consult to manage warfarin (COUMADIN)	STAT, Until discontinued, Starting S Indication:
[] Mechanical Prophylaxis (Single Response) (Se	
Required)	
() Contraindications exist for mechanical prophylaxis	Routine, Once No mechanical VTE prophylaxis due to the following contraindication(s): PACU & Post-op
( ) Place/Maintain sequential compression device continuous	Routine, Continuous, PACU & Post-op
Labs Today	
Hematology/Coagulation	
[] Hemoglobin and hematocrit	Once, Post-op
CBC with platelet and differential	Once, Post-op
Prothrombin time with INR	Once, Post-op
Partial thromboplastin time	Once, Post-op
Chemistry	
[] Basic metabolic panel	Once, Post-op
Magnesium	Once, Post-op
[] Calcium	Once, Post-op
[] Thromboelastograph	Once Anticoagulant Therapy:
	Diagnosis:
	Fax Number (For TEG Graph Result): Post-op
Labs Tomorrow	
Hematology/Coagulation	
Hemoglobin and hematocrit	AM draw For 1 Occurrences, Post-op
[] CBC with platelet and differential	AM draw For 1 Occurrences, Post-op
·	•

Prothrombin time with INR     Partial thromboplastin time	AM draw For 1 Occurrences, Post-op  AM draw For 1 Occurrences, Post-op
[] Fattai tillombopiasiin time	Aivi diaw i of i Occurences, rost-op
Chemistry	
[] Basic metabolic panel	AM draw For 1 Occurrences, Post-op
[] Magnesium	AM draw For 1 Occurrences, Post-op
[] Calcium	AM draw For 1 Occurrences, Post-op AM draw For 1 Occurrences
[] Thromboelastograph - In AM on post-operative day #1	Anticoagulant Therapy:
	Diagnosis:
	Fax Number (For TEG Graph Result):
	In AM on post-operative day #1, Post-op
[] Thromboelastograph - at noon on post-operative day #1	Timed, Starting S+1 at 12:00 PM For 1 Occurrences Anticoagulant Therapy:
	Diagnosis:
	Fax Number (For TEG Graph Result):
	At Noon on post-operative day #1, Post-op
Cardiology	
Imaging	
X-Ray	
[] Chest 1 Vw Portable	Routine, 1 time imaging, Starting S at 1:00 AM For 1,
	Post-op
Other Studies	
Respiratory	
Respiratory	
[X] Incentive spirometry	Routine, Every hour
[X] moontive sphometry	While awake, Post-op
Rehab	
Consults	
For Physician Consult orders use sidebar	
Aveille we Consolle	
Ancillary Consults	
[] Consult to Case Management	Consult Reason: Post-op
[] Consult to Social Work	Reason for Consult:
	Post-op
[] Consult PT eval and treat	Reasons for referral to Physical Therapy (mark all applicable)
	Are there any restrictions for positioning or mobility? Please provide safe ranges for HR, BP, O2 saturation(if
	values are very abnormal):
	Weight Bearing Status:
	Post-op
[] Consult PT wound care	Special Instructions:
	Location of Wound? Post-op
	ι υστ-υρ

[] Consult OT eval and treat	Reason for referral to Occupational Therapy (mark all that apply): Are there any restrictions for positioning or mobility? Please provide safe ranges for HR, BP, O2 saturation( if values are very abnormal): Weight Bearing Status: Post-op
[] Consult to Nutrition Services	Reason For Consult? Purpose/Topic: Post-op
[] Consult to Spiritual Care	Reason for consult? Post-op
[] Consult to Speech Language Pathology	Routine, Once Reason for consult: Post-op
[] Consult to Wound Ostomy Care nurse	Reason for consult: Reason for consult: Reason for consult: Reason for consult: Consult for NPWT: Reason for consult: Reason for consult: Post-op
[] Consult to Respiratory Therapy	Reason for Consult? Post-op

Additional Orders